Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine.
Endostatin is an important endogenous inhibitor of neovascularization, which has been widely used in anti-angiogenesis therapy for cancer. To fully explore the potential of endostatin, we evaluated the anti-tumor efficacy of the combination of recombinant human endostatin adenovirus and low-dose gemcitabine in nude mice. We injected recombinant human endostatin adenovirus intratumorally plus a low dose of gemcitabine i.p. routinely. The combination treatment produced no side-effects, and resulted in marked suppression in tumor formation and growth of established human lung carcinoma xenografts in nude mice, with decreased microvessel density and increased apoptosis percentage. Our data support the idea of synergistic anti-tumor properties of endostatin plus low-dose chemotherapy against human lung cancer in vivo.
Wu
Yang
Y
State Key Laboratory of Biotherapy for Human Diseases, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, PRC.
Yang
Li
L
Hu
Bing
B
Liu
Ji-Yan
JY
Su
Jing-Mei
JM
Luo
Yan
Y
Ding
Zhen-Yu
ZY
Niu
Ting
T
Li
Qiu
Q
Xie
Xing-Jiang
XJ
Wen
Yan-Jun
YJ
Tian
Ling
L
Kan
Bing
B
Mao
Yong-Qiu
YQ
Wei
Yu-Quan
YQ
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004357:Drug Synergism; D043169:Endostatins / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D015552:Injections, Intralesional; D007274:Injections, Intraperitoneal; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D043169:Endostatins; D011994:Recombinant Proteins; D003841:Deoxycytidine; D000093542:Gemcitabine